Walleye Capital
BPMC

Walleye Capital’s Blueprint Medicines BPMC Stock Holding History

Walleye Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,830
Closed -$2.16M – 4532
2025
Q2 		$2.16M Sell
16,830
-25,365
-60% -$2.63M 0.01% 1451
2025
Q1 		$3.73M Buy
42,195
+14,305
+51% +$1.4M 0.02% 977
2024
Q4 		$2.43M Buy
27,890
+24,641
+758% +$2.26M 0.01% 1603
2024
Q3 		$301K Sell
3,249
-6,495
-67% -$645K ﹤0.01% 3721
2024
Q2 		$1.05M Buy
9,744
+8,156
+514% +$816K ﹤0.01% 2799
2024
Q1 		$151K Buy
+1,588
New +$136K ﹤0.01% 4155
2022
Q3 		– Sell
-5,234
Closed -$264K – 3230
2022
Q2 		$264K Buy
+5,234
New +$307K 0.01% 1386
2022
Q1 		– Sell
-15,461
Closed -$1.66M – 2300
2021
Q4 		$1.66M Buy
+15,461
New +$1.62M 0.05% 381
2020
Q3 		– Sell
-2,628
Closed -$205K – 841
2020
Q2 		$205K Buy
+2,628
New +$178K 0.05% 425

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Walleye Capital's BPMC Position: Q3 2025 in Review

Walleye Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 16,830 shares — an estimated $2.16M sold.

Walleye Capital first reported a position in BPMC in Q2 2020 and held it in 9 quarters. The position peaked at $3.73M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Walleye Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 16,830 Blueprint Medicines shares in Q3 2025, an estimated $2.16M.
  • Walleye Capital first reported a position in Blueprint Medicines in Q2 2020 and held it in 9 quarters.
  • Walleye Capital's Blueprint Medicines position peaked at $3.73M in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.